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Abstract
Spatial dispersion of repolarization in the form of transmural, trans-septal and apico-basal
dispersion of repolarization creates voltage gradients that inscribe the J wave and T wave of the
ECG. Amplification of this spatial dispersion of repolarization (SDR) underlies the develop-
ment of life-threatening ventricular arrhythmias associated with inherited or acquired ion
channelopathies giving rise to the long QT, short QT and Brugada syndromes (BrS). This
review focuses on the role of spatial dispersion of repolarization in drug-induced
arrhythmogenesis associated with the long QT and BrS. In the long QT syndrome, drug-
induced amplification of SDR is often secondary to preferential prolongation of the action
potential duration (APD) of M cells, whereas in the BrS, it is thought to be due to selective
abbreviation of the APD of right ventricular epicardium. Among the challenges ahead is the
identification of a means to quantitate SDR non-invasively. This review also discusses the
value of the interval between the peak and end of the T wave (Tpeak–Tend, Tp–Te) as an index of
SDR and transmural dispersion of repolarization, in particular. (Cardiol J 2008; 15: 100–121)
Key words: LQT syndrome, Brugada syndrome, spatial dispersion of
repolarization, channelopathies
Introduction
Heterogeneities of ventricular repolarization
have long been implicated in arrhythmogenesis. It
is well established that ventricular myocardium is
comprised of at least three electrophysiologically
and functionally distinct cell types: epicardial, M and
endocardial cells [1, 2]. These three principal ven-
tricular myocardial cell types differ with respect to
phase 1 and phase 3 repolarization characteristics.
Ventricular epicardial and M, but not endocardial,
cells generally display a prominent phase 1, due to
a large 4-aminopyridine (4-AP) sensitive transient
outward current (Ito), giving the action potential
a spike and dome or notched configuration. These
regional differences in Ito, first suggested on the
basis of action potential data [3], have now been
directly demonstrated in canine [4], feline [5], rab-
bit [6], rat [7], and human [8, 9] ventricular myocytes.
Differences in the magnitude of the action poten-
tial notch and corresponding differences in Ito have
also been described between right and left ventricu-
lar epicardial and M cells [10, 11]. This distinction is
thought to form the basis for why the Brugada syn-
drome (BrS), a channelopathy-mediated form of sud-
den death, is a right ventricular disease.
Between surface epicardial and endocardial lay-
ers are layers of transitional and M cells. M cells
are distinguished by the ability of their action po-
tential to prolong disproportionately relative to the
action potential of other ventricular myocardial cells
in response to a slowing of rate and/or in response
to action potential duration (APD)-prolonging
agents [1, 12, 13]. In the dog, the ionic basis for
these features of the M cell include the presence
of a smaller slowly activating delayed rectifier current
(IKs) [14], a larger late sodium current (late INa) [15]
and a larger Na–Ca exchange current (INa–Ca) [16].
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In the canine heart, the rapidly activating delayed
rectifier (IKr) and inward rectifier (IK1) currents are
similar in the three transmural cell types. Trans-
mural and apico-basal differences in the density of
IKr channels have been described in the ferret he-
art [17]. IKr message and channel protein are much
larger in the ferret epicardium. IKs is larger in M
cells isolated from the right vs. left ventricles of the
dog [11]. Calcium current (Ica) has been shown to
be similar among cells isolated from epicardium, M,
and endocardial regions of the left ventricular wall
[18, 19]. One study however reported differences
in Ca2+ channel properties between epicardial and
endocardial canine ventricular cells with endocar-
dial cells displaying a larger current [20].
The distribution of M cells within the ventri-
cular wall has been investigated in greatest detail
in the left ventricle of the canine heart. Although
transitional cells are found throughout the wall in
the canine left ventricle, M cells displaying the lon-
gest action potentials [at basic cycle lengths
(BCLs) ≥ 2000 ms] are often localized in the deep
subendocardium to midmyocardium in the anterior
wall [21], deep subepicardium to midmyocardium
in the lateral wall [12] and throughout the wall in
the region of the right ventricular (RV) outflow
tracts [2]. M cells are also present in the deep cell
layers of endocardial structures, including papil-
lary muscles, trabecule and the interventricular
septum [22]. Unlike Purkinje fibers, M cells are
not found in discrete bundles or islets [22, 23], al-
though there is evidence that they may be locali-
zed in discrete muscle layers. Cells with the cha-
racteristics of M cells have been described in the
canine, guinea pig, rabbit, pig and human ventric-
les [4, 12–14, 21–41].
Transmural, trans-septal and apico-basal hete-
rogeneities of final repolarization of the action po-
tential within ventricular myocardium are thought to
be responsible for inscription of the T wave [39, 42].
Studies involving the arterially-perfused wedge
have shown that currents flowing down voltage gra-
dients on either side of the M region are in large
part responsible for the T wave [39]. The interplay
between these opposing forces establishes the he-
ight and width of the T wave and the degree to
which either the ascending or descending limb of
the T wave is interrupted, leading to a bifurcated
or notched appearance of the T wave [39]. The vol-
tage gradients result from a more positive plateau
potential in the M region than in epicardium or en-
docardium as well as from differences in the time-
course of phase 3 of the action potential of the three
predominant ventricular cell types.
Under normal and most long QT conditions, the
epicardial response is the earliest to repolarize and the
M cell action potential is often the last. Full repolariza-
tion of the epicardial action potential is coincident with
peak of the T wave and repolarization of the M cells
coincides with the end of the T wave. Thus, the repo-
larization of the M cells in the heart usually determine
the QT interval. The interval between the peak and end
of the T wave (Tp–Te) has been suggested to provi-
de an index of transmural dispersion of repolariza-
tion, which may be of prognostic value [39, 43].
Although apico-basal repolarization gradients
have been suggested to play a prominent role in the
registration of the T wave, particularly T waves
changes associated with cardiac memory [42, 44]
studies involving coronary-perfused wedge prepa-
rations suggest little or no contribution under ba-
seline conditions and greater contribution of global
dispersion of repolarization to T wave changes as-
sociated with cardiac memory [39, 45].
The long QT syndrome
Prolongation of the action potential duration of
the M cell usually underlies the prolongation of the
QT interval on the surface ECG, the time interval
between ventricular depolarization and repolariza-
tion. Prolongation of the QT can occur as a conse-
quence of congenital defects or in response to drugs
that prolong the APD via a reduction in IKs, IKr or the
inward rectifier potassium current (IK1), or an incre-
ase in calcium current (ICa) or late sodium current
(INa). The inherited forms of the long QT syndrome
(LQTS) are phenotypically and genotypically diver-
se, but have in common the appearance of long QT
interval in the ECG, an atypical polymorphic ven-
tricular tachycardia known as torsade de pointes
(TdP), and, in many but not all cases, a relatively
high risk for sudden cardiac death [46–48]. Conge-
nital LQTS is subdivided into ten genotypes distin-
guished by mutations in at least seven different ion
genes and in structural anchoring protein located
on chromosomes 3, 4, 6, 7, 11, 17 and 21 (Table 1)
[49–56]. Timothy syndrome, also referred to as
LQT8, is a rare congenital disorder characterized
by multi-organ dysfunction including prolongation
of the QT interval, lethal arrhythmias, webbing of
fingers and toes, congenital heart disease, immune
deficiency, intermittent hypoglycemia, cognitive
abnormalities, and autism. Timothy syndrome has
been linked to loss of voltage-dependent inactiva-
tion due to mutations in Cav1.2, the gene that enco-
des for an a subunit of the calcium channel [57]. The
most recent genes associated with LQTS are CAV3
102
Cardiology Journal 2008, Vol. 15, No. 2
www.cardiologyjournal.org
which encodes caveolin-3 and SCN4B which enco-
des NaVB4, an auxiliary subunit of the cardiac so-
dium channel. Mutations in both genes produce
a gain of function in late INa, causing an LQT3-like
phenotype [55, 56].
Two patterns of inheritance have been identi-
fied: 1) a rare autosomal recessive disease associa-
ted with deafness (Jervell and Lange-Nielsen), cau-
sed by 2 genes that encode for the slowly activa-
ting delayed rectifier potassium channel (KCNQ1
and KCNE1); and 2) a much more common autoso-
mal dominant form known as the Romano-Ward
syndrome, caused by mutations in 10 different ge-
nes, including KCNQ1 (KvLQT1; LQT1); KCNH2
(HERG;LQT2); SCN5A (Nav1.5; LQT3); ANKB
(LQT4); KCNE1 (minK; LQT5); KCNE2 (MiRP1;
LQT6); KCNJ2 (LQT7; Andersen’s syndrome),
CACNA1C (Cav1.2; LQT8; Timothy syndrome),
CAV3 (Caveolin-3; LQT9) and SCN4B (NaVB4,
LQT10). Six of the 10 genes encode for cardiac po-
tassium channels, one for the cardiac sodium chan-
nel (SCN5A), one for the b subunit of the sodium
channel, one for caveolin-3 and one for a protein
called Ankyrin B (ANKB), which is involved in an-
choring of ion channels to the cellular membrane.
Acquired LQTS refers to a syndrome similar
to the congenital form but caused by exposure to
drugs that prolong the duration of the ventricular
action potential [58] or QT prolongation secondary
to cardiomyopathies such as dilated or hypertrophic
cardiomyopathy, as well as to abnormal QT prolon-
gation associated with bradycardia or electrolyte
imbalance [59–63].
Table 2 presents a list of drugs known to pro-
long the QT interval and to induce torsade de poin-
tes. Most of these drugs block IKr, many also block
IKs, and some augment late INa, so that in many ways
they are similar to congenital forms of LQTS. The
acquired form of the disease is far more prevalent
than the congenital form, and in some cases may
have a genetic predisposition.
The ability of genetic mutations and drugs to
amplify spatial dispersion of repolarization within
the ventricular myocardium has been identified as
the principal arrhythmogenic substrate in both acqu-
ired and congenital LQTS. Early- and in some ca-
ses delayed-afterdepolarizations have been identi-
fied as triggers responsible for the precipitation of
torsade de pointes. The accentuation of spatial
dispersion, typically secondary to an increase of
transmural, trans-septal or apico-basal dispersion
of repolarization, and the development of early after-
depolarization (EAD)-induced triggered activity
underlie the substrate and trigger for the develop-
ment of torsade de pointes arrhythmias observed
under LQTS conditions [64, 65]. Models of the
LQT1, LQT2, LQT3, LQT5, LQT6, LQT7 and
LQT8 forms of the long QT syndrome have been
developed using the canine arterially perfused left
ventricular wedge preparation [66–69]. These mo-
dels suggest that in LQT1–3, 4, and 8 preferential
prolongation of the M cell APD can lead to an
Table 1. Inherited disorders caused by ion channelopathies
Rhythm Inheritance Locus Ion channel Gene
Long QT syndrome (RW) TdP AD
LQT1 11p15 IKs KCNQ1, KvLQT1
LQT2 7q35 IKr KCNH2, HERG
LQT3 3p21 INa SCN5A, Nav1.5
LQT4 4q25 ANKB, ANK2
LQT5 21q22 IKs KCNE1, minK
LQT6 21q22 IKr KCNE2, MiRP1
LQT7 (Andersen-Tawil syndrome) 17q23 IK1 KCNJ2, Kir 2.1
LQT8 (Timothy syndrome) 6q8A ICa CACNA1C,Cav1.2
LQT9 3p25 INa CAV3, Caveolin-3
LQT10 11q23.3 INa SCN4B. Navb4
LQT syndrome (JLN) TdP AR 11p15 IKs KCNQ1, KvLQT1
21q22 IKs KCNE1, minK
Brugada syndrome BrS1 PVT AD 3p21 INa SCN5A, Nav1.5
BrS2 PVT AD 3p24 INa GPD1L
BrS3 PVT AD 12p13.3 ICa CACNA1C,CaV1.2
BrS4 PVT AD 10p12.33 ICa CACNB2b, Cavb2b
AD — autosomal dominant; AR — autosomal recessive; JLN — Jervell and Lange-Nielsen; LQT — long QT; RW — Romano-Ward; TdP — torsade de
pointes; VF — ventricular fibrillation; VT — ventricular tachycardia; PVT — polymorphic VT
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increase in the QT interval as well as an increase
in transmural dispersion of repolarization (TDR),
which contributes to the development of spontane-
ous as well as stimulation-induced TdP [32, 37, 70].
The distinctive characteristics of the M cells
are at the heart of the long QT syndrome. The hall-
mark of the M cell is the ability of its action poten-
tial to prolong more than that of epicardium or endo-
cardium in response to a slowing of rate [2, 12, 71].
As previously detailed, this feature of the M cell is
due to weaker repolarizing current during phases
2 and 3 secondary to a smaller IKs and a larger late
INa and INa–Ca [14–16] compared to epicardial and en-
docardial cells. These ionic distinctions sensitize
the M cells to a variety of pharmacological agents
and pathophysiological states. Agents that block IKr,
IKs or increase ICa or late INa generally produce a much
greater prolongation of the APD of the M cell than
of epicardial or endocardial cells.
Experimental models that mimic the clinical
congenital syndromes with respect to prolongation
of the QT interval, T wave morphology, rate depen-
dence of QT have also been helpful in elucidation
of the basis for sympathetic nervous system influ-
ences [21, 32, 37–39].
IKs block using chromanol 293B is used to mi-
mic LQT1. IKs block alone produces a homogene-
ous prolongation of repolarization and refractoriness
across the ventricular wall and does not induce ar-
rhythmias. The addition of isoproterenol causes
abbreviation of epicardial and endocardial APD but
a prolongation or no change in the APD of the M
cell, resulting in a marked augmentation of TDR and
the development of spontaneous and stimulation-
induced TdP [37]. These changes give rise to a bro-
ad based T wave and the long QT interval charac-
teristics of LQT1. The development of TdP in the
model requires b adrenergic stimulation, consistent
with a high sensitivity of congenital LQTS, LQT1 in
particular, to sympathetic stimulation [46–48, 72, 73].
IKr block using d-Sotalol has been used to mi-
mic LQT2 and provides a model of the most com-
mon form of acquired (drug-induced) LQTS. A gre-
ater prolongation of the M cell action potential and
slowing of phase 3 of the action potential of all three
cell types results in a low amplitude T wave, long
Table 2. Drugs with risk of long QT syndrome and torsade de pointes.
Generic name Class/clinical use







Disopyramide Anti-arrhythmic/abnormal heart rhythm
Dofetilide Anti-arrhythmic/abnormal heart rhythm
Domperidone* Anti-nausea/nausea
Droperidol Sedative; anti-nausea/anesthesia adjunct, nausea
Erythromycin Antibiotic; GI stimulant/bacterial infection; increase GI motility
Halofantrine Anti-malarial/malaria infection
Haloperidol Anti-psychotic/schizophrenia, agitation
Ibutilide Anti-arrhythmic/abnormal heart rhythm
Levomethadyl Opiate agonist/pain control, narcotic dependence
Mesoridazine Anti-psychotic/schizophrenia
Methadone Opiate agonist/pain control, narcotic dependence
Pentamidine Anti-infective/pneumocystis pneumonia
Pimozide Anti-psychotic/Tourette’s tics
Procainamide Anti-arrhythmic/abnormal heart rhythm
Quinidine Anti-arrhythmic/abnormal heart rhythm
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QT interval, large transmural dispersion of repola-
rization and the development of spontaneous as well
as stimulation-induced TdP. The addition of hypo-
kalemia gives rise to low-amplitude T waves with
a deeply notched or bifurcated appearance, similar
to those commonly seen in patients with the LQT2
syndrome [32, 39]. Isoproterenol further exagge-
rates transmural dispersion of repolarization, thus
increasing the incidence of TdP [70].
ATX-II, an agent that increases late INa, is used
to mimic LQT3 [32]. ATX-II markedly prolongs the
QT interval, delays the onset of the T wave, in some
cases also widening it, and produces a sharp rise in
transmural dispersion of repolarization as a result
of a greater prolongation of the APD of the M cell.
The differential effect of ATX-II to prolong the M
cell action potential is likely due to the presence of
a larger late sodium current in the M cell [15]. ATX-II
produces a marked delay in onset of the T wave
because of a relatively large effect of the drug on
epicardial and endocardial APD. This feature is con-
sistent with the late-appearing T wave (long iso-
electric ST segment) observed in patients with the
LQT3 syndrome. Also in agreement with the clini-
cal presentation of LQT3, the model displays a ste-
ep rate dependence of the QT interval and deve-
lops TdP at slow rates. Interestingly, b adrenergic
influence in the form of isoproterenol reduces trans-
mural dispersion of repolarization by abbreviating
the APD of the M cell more than that of epicardium
or endocardium, and thus reducing the incidence of
TdP. While the beta-adrenergic blocker proprano-
lol is protective in LQT1 and LQT2 wedge models,
it has the opposite effects in LQT3, acting to am-
plify transmural dispersion and promoting TdP [70].
It is interesting that the response to sympathe-
tic activation displays a very different time-course
in the case of LQT1 and LQT2, both in experimen-
tal models and in the clinic [65, 74]. In LQT1,
b adrenergic stimulation induces an increase in TDR
that is most prominent during the first two minutes,
but which persists, although to a lesser extent, du-
ring steady-state. Torsade de pointes incidence is en-
hanced during the initial period as well as during ste-
ady-state. In LQT2, isoproterenol produces only
a transient increase in TDR that persists for less than
2 minutes. Torsade de pointes incidence is therefo-
re enhanced only for a brief period of time. These
differences in time-course may explain the impor-
tant differences in autonomic activity and other gene-
specific triggers that contribute to events in patients
with different LQTS genotypes [65, 73, 75].
Figure 1 presents a working hypothesis for our
understanding of the mechanisms underlying
LQTS-related TdP based on available data. The
hypothesis presumes the presence of electrical
heterogeneity in the form of transmural or trans-
septal dispersion of repolarization under baseline
conditions and the amplification of TDR by agents
that reduce net repolarizing current via a reduction
Figure 1. Proposed cellular mechanism for the development of torsade de pointes in the long QT syndromes.
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in IKr or IKs or augmentation of ICa or late INa. Condi-
tions that cause a reduction in IKr or augmentation
of late INa lead to a preferential prolongation of the
M cell action potential. As a consequence, the QT
interval prolongs and is accompanied by a dramatic
increase in transmural dispersion of repolarization,
thus creating a vulnerable window for the develop-
ment of reentry. The reduction in net repolarizing
current also predisposes to the development of
EAD-induced triggered activity in M and Purkinje
cells, which provide the extrasystole that triggers
TdP when it falls within the vulnerable period. Beta-
adrenergic agonists further amplify transmural he-
terogeneity (transiently) in the case of IKr block, but
reduce it in the case of INa agonists [30, 70].
Although conditions that prolong QT are often
associated with an increase in TDR, this is not al-
ways the case. Amiodarone, a potent antiarrhyth-
mic agent used in the management of both atrial and
ventricular arrhythmias, is rarely associated with
TdP [76]. Chronic administration of amiodarone
produces a greater prolongation of APD in epicar-
dium and endocardium, but less of an increase in
APD, or even a decrease at slow rates, in the M
region, thereby reducing TDR [77]. In a dog model
of chronic complete atrioventricular block and acqu-
ired LQTS, 6 weeks of amiodarone was shown to
produce a major QT prolongation without producing
TdP. In contrast, after 6 weeks of dronedarone, TdP
occurred in 4 of 8 dogs displaying the highest spa-
tial dispersion of repolarization (105 ± 20 ms) [78]
Sodium pentobarbital is another agent that prolongs
the QT interval but reduces TDR. Pentobarbital has
been shown to produce a dose-dependent prolon-
gation of the QT interval, accompanied by a reduc-
tion in TDR from 51 to 27 ms [36]. TdP is not obse-
rved under these conditions, nor can it be induced
with programmed stimulation. Amiodarone and
pentobarbital have in common the ability to block
IKs, IKr, and late INa. This combination produces
a preferential prolongation of the APD of epicardium
and endocardium so that the QT interval is prolon-
ged, but TDR is actually reduced and TdP does not
occur.
Cisapride, another agent that blocks both in-
ward and outward currents, produces a biphasic
concentration-dependent prolongation of the QT
interval. A parallel biphasic dose-response relation-
ship is seen for TDR, peaking at 0.2 mM, and it is
only at this concentration that TdP is observed.
Higher concentrations of cisapride further prolong
QT, but reduced TDR, thereby preventing TdP in-
duction [79]. This finding suggests that the spatial
dispersion of repolarization is more important than
the prolongation of the QT interval in determining
the substrate for TdP.
The IKs blocker, chromanol 293B, is another
agent that increases QT without augmenting TDR.
Chromanol 293B prolongs APD of the 3 cell types
homogeneously, neither increasing TDR nor wide-
ning the T wave. TdP is not observed under these
conditions. Although an arrhythmogenic substrate
is not present with IKs block alone, it develops very
quickly with the introduction of b adrenergic stimu-
lation. Isoproterenol abbreviates the APD of epicar-
dial and endocardial cells but not that of the M cell,
resulting in a marked accentuation of TDR [70].
Torsade de pointes readily develops under these
conditions.
These observations have advanced our under-
standing of why long-QT patients, LQT1 in parti-
cular, are so sensitive to sympathetic influences,
and have provided further evidence in support of
the hypothesis that the risks associated with LQTS
are not due to the prolongation of the QT interval
but rather to an increase in spatial dispersion of
repolarization that usually, but not always, accom-
panies the prolongation of the QT interval.
Thus, QT prolonging agents display very dif-
ferent concentration-dependent behavior. Pure IKr
blockers such as sotalol, dofetilide and erythromy-
cin produce a dose-dependent prolongation of the
QT interval that is associated with a dose-depen-
dent prolongation of TDR. When TDR reaches the
threshold for re-entry, which in the canine wedge
preparation is approximately 90 ms, TdP will occur.
With more complex agents such as quinidine and
cisapride there is a biphasic dose-response rela-
tionship. TDR parallels QT, but the two can peak
at different concentrations. TdP occurs when and
if TDR reaches the threshold value. Still other
drugs produce a dose-dependent prolongation of
QT, but a smaller increase or even a decrease in
TDR; threshold values for TdP are rarely reached.
Finally, agents that preferentially block IKs such as
chromanol 293B, and agents with multiple ion
channel effects including pentobarbital, amiodaro-
ne, and the new anti-anginal agent ranolazine, pro-
duce a dose-dependent prolongation of the QT in-
terval that is not associated with an increase in
TDR. Torsade de pointes rarely, if ever, occurs
under these conditions.
Thus, TdP is not produced by drugs that cause
a dose-dependent prolongation of QT but a reduc-
tion of TDR or little or no increase in TDR. Taken
together these findings indicate that arrhythmoge-
nesis in the long QT syndromes is not due to pro-
longation of QT interval but rather to the increase
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in TDR that often accompanies prolongation of the
QT interval. The ability of sympathetic influences
to dramatically increase TDR also explains why
LQT1 and LQT2 patients are so sensitive to sym-
pathetic stimulation.
Tpeak–Tend as a non-invasive marker
of spatial dispersion of repolarization
If QT prolongation is not prognostic of risk for
the development of life-threatening arrhythmias is
there a better index? While a number of promising
approaches have been pursued in recent years, our
interest has been in the interval between the peak
and the end of the T wave (Tpeak–Tend interval). Dif-
ferences in the time-course of repolarization of the-
se three predominant ventricular myocardial cell
types contribute prominently to the inscription of
the electrocardiographic T wave recorded in the
precordial leads [39]. These differences in action
potential morphology lead to the development of
opposing voltage gradients on either side of the M
region, which contribute to inscription of the T
wave, especially those inscribed in the precordial
leads (Fig. 1) [39]. Apico-basal gradients are tho-
ught to contribute to the T wave as well, especially
in the limb lead where the polarity of the T wave
may be opposite to that recorded in the precordial
leads [42]. The interplay between these opposing
transmural forces determines the height and width
of the T wave and the extent to which the T wave
may be interrupted, resulting in a bifid or notched
appearance.
When the T wave is upright, the epicardial re-
sponse is the earliest to repolarize and the M cell
action potential is the last. Full repolarization of the
epicardial action potential coincides with the peak
of the T wave and repolarization of the M cells is
coincident with the end of the T wave. It therefore
follows that the duration of the M cell action poten-
tial determines the QT interval, whereas the dura-
tion of the epicardial action potential determines the
QTpeak interval. Another interesting finding stem-
ming from these studies was that the Tpeak–Tend in-
terval may provide an index of transmural disper-
sion of repolarization [2, 39]. Figure 2 illustrates
these relationships under baseline and long QT
conditions. ATX-II, a sea anemone toxin, mimics the
LQT3 form of the long QT syndrome by augmen-
ting the late sodium current, which helps to susta-
in the plateau of the action potential. ATX-II, like
most agents that prolong the action potential, cau-
ses a preferential prolongation of the M cell respon-
se, thus producing a dramatic accentuation of the
transmural dispersion of repolarization, which is
reflected on the ECG as a prolongation of the
Tpeak–Tend interval. An increase in transmural disper-
sion of repolarization is a common feature of all
LQTS models and has been shown to provide the
substrate for the development of TdP under long
QT conditions [2, 32, 70].
Based on these and similar studies, the Tpeak–Tend
interval in precordial ECG leads was suggested to
provide an index of transmural dispersion of repo-
larization [2]. More recent studies have also provi-
ded guidelines for the estimation of transmural di-
spersion of repolarization in the case of more com-
plex T waves, including negative, biphasic and
triphasic T waves [80]. In such cases, the interval
from the nadir of the first component of the T wave
to the end of the T wave was shown to provide an
electrocardiographic approximation of TDR.
While these relationships are relatively stra-
ight forward in the coronary-perfused wedge pre-
paration, extrapolation to the surface ECG recor-
ded in vivo must be approached with great caution
and will require careful validation. The Tpeak–Tend
interval is unlikely to provide an absolute measure
of transmural dispersion in vivo, as demonstrated
by Xia et al. [81]. However, changes in this para-
meter are thought to be capable of reflecting chan-
ges in spatial dispersion of repolarization, including
TDR, and thus may be prognostic of arrhythmic risk
under a variety of conditions [82–87]. Takenaka et
al. [86] recently demonstrated exercise-induced ac-
centuation of the Tpeak–Tend interval in LQT1 pa-
tients. These observations coupled with those of
Schwartz et al. [75], demonstrating an association
between exercise and risk for TdP in LQT1, pa-
tients, pointed to the potential value of Tpeak–Tend in
forecasting risk for the development of torsade de
pointes. Direct evidence in support of Tpeak–Tend as
an index to predict TdP in patients with LQTS has
recently been provided by a number of studies.
Yamaguchi et al. [88] showed that Tpeak–Tend is more
valuable than QTc and QT dispersion as a predic-
tor of TdP in patients with acquired LQTS. Shimi-
zu et al. [85] demonstrated that Tpeak–Tend, but not
QTc, predicted sudden cardiac death in patients
with hypertrophic cardiomyopathy. In a case-con-
trolled study comparing 30 cases of acquired bra-
dyarrhythmias complicated by TdP and 113 cases
with uncomplicated bradyarrhythmias, Topilski et
al. [89] found that QT, QTc and Tpeak–Tend intervals
were strong predictors of TdP, with the best single
discriminator being a prolonged Tpeak–Tend. Watana-
be et al. [87] demonstrated that prolonged Tpeak–Tend
is associated with inducibility as well as spontaneous
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development of ventricular tachycardia (VT) in high
risk patients with organic heart disease.
These interesting studies demonstrating an
association between an increase in Tpeak–Tend and
arrhythmic risk notwithstanding, direct validation
of Tpeak–Tend measured at the body surface as an in-
dex of TDR is still lacking. Guidelines for such va-
lidation have been suggested [39, 80, 90]. Because
precordial leads view the electrical field across the
ventricular wall, Tpeak–Tend would be expected to be
most representative of TDR in these leads. The
precordial leads are unipolar leads placed on the
chest that are referenced to Wilson central termi-
nal. The direction of these leads is radially toward
the “center” of the heart, the center of the Eintho-
ven triangle. Unlike the precordial leads, the bipo-
lar limb leads, including leads I, II, and III, do not
look across the ventricular wall. While Tpeak–Tend
intervals measured in these limb leads may provi-
de an index of TDR, they are more likely to reflect
global dispersion, including apico-basal and inte-
rventricular dispersion of repolarization [81, 91].
A large increase in TDR is likely to be arrhy-
thmogenic because the dispersion of repolarization
and refractoriness occurs over a very short distan-
ce (the width of the ventricular wall), creating
a steep repolarization gradient [92, 93]. It is the
steepness of the repolarization gradient rather
than the total magnitude of dispersion that deter-
mines its arrhythmogenic potential [92, 93]. Api-
co-basal or interventricular dispersion of repola-
rization is less informative because it may or may
not be associated with a steep repolarization gra-
dient and thus may or may not be associated with
arrhythmic risk.
Another important consideration is that TDR
can be highly variable in different regions of the
ventricular myocardium, particularly under patho-
physiologic conditions. Consequently, it is impor-
tant to measure Tpeak–Tend independently in each of
the precordial leads and it is inadvisable to average
Tpeak–Tend among several leads [81]. Yamaguchi
et al. [88] in their study of acquired LQTS targeted
lead V5. In contrast, because BrS is a right
Figure 2. Electrocardiographic Tpeak–Tend interval as a measure of transmural dispersion of repolarization. The figure
shows the correspondence among transmembrane, unipolar, and ECG recordings in the absence (left) and the
presence (right) of ATX-II (20 nmol/L). Each panel shows: A. Transmembrane action potentials recorded from M (M2)
and epicardial sites of a canine left ventricular wedge preparation together with a transmural ECG recorded across
the bath (BCL of 2000 ms); B. Eight intramural unipolar electrograms recorded approximately 1.2 mm apart from
endocardial (Endo), M (6 sites; M1–M6) and epicardial (Epi) regions (120 mm silver electrodes insulated except at the
tip) inserted midway into the wedge preparation. Dashed vertical lines in the unipolar electrograms denote the time
maximum of the first derivative (Vmax) of the T wave (ARI, end of activation-recovery interval). Close correspondence
between the repolarization time of the cells deep within the wedge and those at the cut surface attest the uniformity
of the electrical activity in the respective transmural layers. Modified from [2], with permission.
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ventricular disorder, Castro et al. [94] targeted lead
V2 in their study of Tpeak–Tend in BrS.
The criteria suggested for validation of Tpeak–Tend
as an index of TDR therefore include a requirement
1) that individual precordial leads, and not bipolar
limb leads, be evaluated; and 2) that TDR be pre-
sent at baseline and significantly augmented as
a result of an intervention.
The quest for direct validation or invalidation
of Tpeak–Tend measured at the body surface as an in-
dex of TDR based on these fundamental criteria re-
mains unfulfilled [91]. Although most studies to date
concur that Tpeak–Tend provides a measure of spatial
dispersion of repolarization, the extent to which an
augmented Tpeak–Tend interval is prognostic of arrhy-
thmic risk depends on the proximity of the regions
displaying disparate repolarization times (i.e., repo-
larization gradient). Consequently, it would be help-
ful to know to what extent Tpeak–Tend provides an in-
dex of TDR, in which case the differences in refrac-
toriness are likely to be within close proximity. An
ideal model in which to test the hypothesis is in the
chronic atrioventricular (AV) block dog treated with
a Class III antiarrhythmic agent, since changes in
Tpeak–Tend could be correlated with TDR in a model
that displays prominent TDR, and additionally cor-
related with the risk for development of TdP.
In addition to pharmacologic agents and patho-
physiological states, interventions that reverse the
direction of activation of the ventricular wall can
augment TDR. In the example illustrated in Figure 3,
reversing the direction of activation of the ventri-
cular wall in the arterially-perfused left ventricular
wedge preparation is shown to lead to a broader and
taller T wave. TDR and Tpeak–Tend are conspicuously
augmented. In the presence of cisapride, reversing
the direction of activation of the left ventricular (LV)
wall, amplifies TDR sufficiently to permit the de-
velopment of torsade de pointes [79]. Figure 4
shows that similar changes in the T wave are re-
corded in the human heart in vivo when the direc-
tion of transmural activation is reversed [95]. Pa-
tients with heart failure were initially paced from
an endocardial site facing lead V5–V6 and then from
an adjacent site on the epicardial surface. The
shift from endocardial to epicardial pacing led to
a dramatic increase in TDR and Tp–Te, similar to
the changes observed in the wedge preparation.
In 4 patients, Tpeak–Tend increased by an average of
24.3%. These data provide evidence in support of
Figure 3. Brugada syndrome phenotype induced by an overdose of desipramine and clonazepam in a 44 year old
man previously medicated with desipramine, clonazepam and trazodone. A. ECG shows sinus bradycardia, first
degree atrioventricular block (228 ms), prolonged QRS interval (132 ms) and downsloping ST elevation (Type 1) in
leads V1–V2, ST elevation in lead V3, upsloping ST depression in leads II, III, and aVF; B. Baseline ECG recorded one
year earlier. Modified from [155] with permission.
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important transmural distinctions in repolarization
across the ventricular wall, for such a change would not
be observed if transmural repolarization was homoge-
neous, as suggested by some studies [42, 91, 96, 97].
A clinical consequence of the increase in TDR
following reversal of the direction of activation of
the ventricular wall was demonstrated by Medina-
-Ravell et al. [98]. These authors reported the first
case in which an upgrade to biventricular pacing in
a patient undergoing resynchronization therapy led
to the development of torsade de pointes. Pacing
via the endocardial electrode in the right ventricu-
lar apex was uneventful. In contrast, pacing via the
left ventricular epicardial lead in the coronary si-
nus resulted in an increase in both QT interval and
Tpeak–Tend, and the development of torsade de poin-
tes. The available data suggest that epicardial acti-
vation of the LV wall during resynchronization the-
rapy is a potential iatrogenic factor in a small sub-
set of patients with prolonged QT intervals and/or
in which TDR is prolonged [95].
Brugada syndrome
In that the BrS is believed to be secondary to
an exaggeration of the J wave, it seems appropriate
to first discuss the basis for the J wave of the ECG.
The presence of a prominent action potential notch
in epicardium but not endocardium gives rise to
a transmural voltage gradient during ventricular
activation that manifests as a late delta wave following
the QRS or what more commonly is referred to as
a J wave [99] or Osborn wave. A distinct J wave is often
observed under baseline conditions in the ECG of
some animal species, including dogs and baboons.
Humans more commonly display a J point elevation
rather than a distinct J wave. A prominent J wave in
the human ECG is considered pathognomonic of hy-
pothermia [100–102] or hypercalcemia [103, 104].
A transmural gradient in the distribution of Ito
is responsible for the transmural gradient in the
magnitude of phase 1 and action potential notch,
which in turn gives rise to a voltage gradient across
the ventricular wall responsible for the inscription
of the J wave or J point elevation in the ECG [3, 4,
105]. Direct evidence in support of the hypothesis
that the J wave is caused by a transmural gradient in
the magnitude of the Ito-mediated action potential
notch derives from experiments conducted in the
arterially-perfused right ventricular wedge prepara-
tion showing a correlation between the amplitude of
the epicardial action potential notch and that of the
 J wave recorded during interventions that alter the
appearance of the electrocardiographic J wave, inc-
luding hypothermia, premature stimulation (restitu-
tion), and block of Ito by 4-aminopyridine (4-AP) [99].
The molecular basis for the transmural distri-
bution of Ito has long been a subject of debate.
Figure 4. Schematic representation of right ventricular epicardial action potential changes proposed to underlie the
electrocardiographic manifestation of the Brugada syndrome. Modified from [173], with permission.
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The transmural gradient of Ito in dog has been ascribed
to a transmural distribution of KCND3 gene (Kv4.3),
which encodes the a subunit of the Ito channel [106]
and a transmural gradient of KChIP2, a b subunit
that coassembles with and serves as a chaperone
for Kv4.3 [107]. The steep transmural gradient of
Ito suggests that spatial patterning of Ito is highly
regulated in mammalian cardiac myocytes. However,
very little is known about transcriptional regulation
of Ito and its components. Recently, a transcriptional
factor, Iroquois 5, was described and shown to regu-
late KCND2 expression [108]. The Iroquois home-
obox (Irx) genes encode a conserved family of trans-
cription factors that specify the identity of diverse
territories in the heart. One of the members of this
family, the homeodomain transcription factor 5
(IRX5), has been shown to contribute to the cardiac
repolarization gradient. IRX5 causes repression of
Kv4.2 expression by recruiting mBop (a cardiac
transcriptional repressor), thus forming an inverse
Ito gradient that contributes to coordinated contrac-
tion of the ventricular wall [18]. In the canine heart,
IRX5 is also expressed in an endocardial-to-epicar-
dial gradient, suggesting that it may regulate expres-
sion of KChIP2 and/or KCND3 genes.
Myocytes isolated from the epicardial region
of the left ventricular wall of the rabbit show a hi-
gher density of cAMP-activated chloride current
when compared to endocardial myocytes [109]. Ito2,
initially ascribed to a K+ current, is now thought to
be primarily due to the calcium-activated chloride
current (ICl(Ca)) is also thought to contribute to the
action potential notch, but it is not known whether
this current, differs among the three ventricular
myocardial cell types [110].
Transmural activation within the relatively thin
wall of RV is relatively rapid causing the J wave to
be buried inside the QRS. Thus, although the ac-
tion potential notch is most prominent in right ven-
tricular epicardium, right ventricular myocardium
would be expected to contribute relatively little to
the manifestation of the J wave under normal con-
ditions. These observations are consistent with the
manifestation of the J wave in ECG leads in which
the mean vector axis is transmurally oriented across
the left ventricle and septum. Accordingly, the
J wave in the dog is most prominent in leads II, III,
aVR, aVF, and mid to left precordial leads V3 through
V6. A similar picture is seen in the human ECG [104,
111]. In addition, vectorcardiography indicates that
the J wave forms an extra loop that occurs at the junc-
tion of the QRS and T loops [112]. It is directed le-
ftward and anteriorly, which explains its prominen-
ce in leads associated with the left ventricle.
To our knowledge, the first description of the
J wave was in the 1920s in animal experiments in-
volving hypercalcemia [103]. The first extensive
description and characterization appeared 30 years
later by Osborn [113] in a study involving experi-
mental hypothermia in dogs. The appearance of
a prominent J wave in the clinic is typically asso-
ciated with pathophysiological conditions, including
hypothermia [100, 111] and hypercalcemia [103,
104]. The prominent J wave induced by hypother-
mia is the result of a marked accentuation of the
spike-and-dome morphology of the action potential
of M and epicardial cells (i.e., an increase in both
width and magnitude of the notch). In addition to
inducing a more prominent notch, hypothermia pro-
duces a slowing of conduction which permits the
epicardial notch to clear the QRS so as to manifest
a distinct J wave. Hypercalcemia-induced accentu-
ation of the J wave [103, 104, 114] may also be expla-
ined on the basis of an accentuation of the epicar-
dial action potential notch, possibly as a result of
an augmentation of the calcium-activated chloride
current and a decrease in ICa [115]. Accentuation of
the action potential notch also underlies the elec-
trocardiographic and arrhythmogenic manifesta-
tions of the BrS.
The Brugada syndrome is characterized by an
accentuated ST segment elevation or J wave appe-
aring principally in the right precordial leads (V1–V3),
often followed by a negative T wave. The syndro-
me, first described in 1992, is generally associated
with a high incidence of sudden cardiac death se-
condary to a rapid polymorphic VT or ventricu-
lar fibrillation (VF) [116]. The average age at the
time of initial diagnosis or sudden death is 40 ± 22.
The youngest patient diagnosed with the syndro-
me is 2 days of age, and the oldest is 84.
The prevalence of the BrS is estimated at 1–5
per 10,000 inhabitants worldwide. The frequency is
lower in western countries and higher (≥ 5 per
10,000) in Southeast Asia, especially Thailand and
the Philippines where BrS is considered to be the
major cause of sudden death in young individuals.
In these countries, the syndrome is often referred
to as sudden unexplained nocturnal death syndro-
me (SUNDS) [117, 118].
Brugada syndrome is inherited via an autoso-
mal dominant mode of transmission. The first gene
to be linked to the BrS is SCN5A, the gene enco-
ding for the a subunit of the cardiac sodium chan-
nel gene [119]. Mutations in SCN5A are also re-
sponsible for the LQT3 form of the long QT syn-
drome and cardiac conduction disease. A number
of mutations have been reported to cause overlapping
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syndromes; in some cases all three phenotypes
are present [120].
Over one hundred mutations in SCN5A have
been linked to the syndrome in recent years (see
[121] for references; also see www.fsm.it/cardmoc).
Only a fraction of these mutations have been stu-
died in expression systems and shown to result in
loss of function due either to: 1) failure of the so-
dium channel to express; 2) a shift in the voltage-
and time-dependence of sodium channel current
(INa) activation, inactivation or reactivation; 3) en-
try of the sodium channel into an intermediate sta-
te of inactivation from which it recovers more slow-
ly or 4) accelerated inactivation of the sodium chan-
nel. In in vitro expression systems, the premature
inactivation of the sodium channel is sometimes
observed at physiological temperatures, but not at
room temperature [122]. Acceleration of INa inacti-
vation was still more accentuated at higher than
physiological temperatures, suggesting that the syn-
drome may be unmasked, and that patients with the
BrS may be at an increased risk, during a febrile sta-
te [122]. A number of Brugada patients displaying
fever-induced polymorphic VT have been identified
since the publication of this report [123–132].
Mutation in the SCN5A gene account for ap-
proximately 18–30% of BrS cases. A higher inciden-
ce of SCN5A mutations has been reported in fami-
lial than in sporadic cases [133]. Of note, negative
SCN5A results generally do not rule out causal gene
mutations, since the promoter region, cryptic spli-
cing mutations or presence of gross rearrangements
are generally not part of routine investigation.
A recent report by Hong et al. [134] provided the first
report of a dysfunctional sodium channel created by
an intronic mutation giving rise to cryptic splice site
activation in SCN5A in a family with the BrS. The
deletion of fragments of segments 2 and 3 of Domain
IV of SCN5A caused complete loss of function.
Bezzina et al. [135] recently provided intere-
sting evidence in support of the hypothesis that
a SCN5A promoter polymorphism common in
Asians modulates variability in cardiac conduction,
and may contribute to the high prevalence of BrS
in the Asian population. Sequencing of the SCN5A
promoter identified a haplotype variant consisting
of 6 polymorphisms in near-complete linkage dise-
quilibrium that occurred at an allele frequency of
22% in Asian subjects and was absent in whites and
blacks. The results of the study demonstrate that
sodium channel transcription in the human heart
may vary considerably among individuals and races
and be associated with variable conduction velocity
and arrhythmia susceptibility.
A second locus on chromosome 3, close to but
distinct from SCN5A, has been linked to the syndro-
me [136] in a large pedigree in which the syndrome
is associated with progressive conduction disease,
a low sensitivity to procainamide, and a relatively
good prognosis. The gene was recently identified as
The glycerol-3-phosphate dehydrogenase 1-like
Gene (GPD1L). A mutation in GPD1L has been
shown to result in a partial reduction of INa [137].
The third and fourth genes associated with the
BrS were reported earlier this year and shown to
encode the a1 (CACNA1C) and b (CACNB2b) sub-
units of the L-type cardiac calcium channel. Muta-
tions in the a and b subunits of the calcium channel
can also lead to a shorter than normal QT interval,
creating a new clinical entity consisting of a combi-
ned Brugada/short QT syndrome [138].
We are currently on a very steep learning curve
in our understanding of the genotype-phenotype re-
lationship in BrS and the role of genetics in the assi-
gnment of risk. It is recommended that all BrS pa-
tients, particularly symptomatic patients, undergo
genetic screening. The argument for genetic testing
is especially compelling in the case of BrS because
the clinical manifestations of BrS generally appear
later in life, in some cases resulting in sudden death
without any warning. Risk stratification of younger
family members is best achieved by genetic screening.
Identification of mutation carriers among family mem-
bers of symptomatic probands alerts the physician to
closely follow these individuals and to proceed with
the implantation of an implantable cardiac defibrilla-
tor (ICD) or other therapy if and when appropriate.
Amplification of epicardial and transmural
dispersion of repolarization secondary to the pre-
sence of genetic defects, pathophysiologic factors
and pharmacologic influences, leads to accentuation
of the J wave and eventually to loss of the action
potential dome, giving rise to extrasystolic activity
in the form of phase 2 reentry. Activation of Ito le-
ads to a paradoxical prolongation of APD in canine
ventricular tissues [139], but to abbreviation of ven-
tricular APD in species that normally exhibit brief
action potentials (e.g., mouse and rat) [140]. Patho-
physiologic conditions (e.g., ischemia, metabolic
inhibition) and some pharmacologic interventions
(e.g., INa or ICa blockers or ATP-sensitive current
(IK-ATP), Ito, IKr or IKs activators) can lead to marked
abbreviation of APD in canine and feline [141] ven-
tricular cells where Ito is prominent. Under these
conditions, canine ventricular epicardium exhibits
an all-or-none repolarization as a result of the shift
in the balance of currents flowing at the end of phase
1 of the action potential. All-or-none repolarization
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of the action potential occurs when phase 1 reaches
approximately –30 mV. This leads to loss of the
action potential dome as the outward currents over-
whelm the inward currents. Loss of the dome ge-
nerally occurs at some epicardial sites but not
others, resulting in the development of a marked
dispersion of repolarization within the epicardium
as well as transmurally, between epicardium and
endocardium. Propagation of the action potential
dome from the epicardial site at which it is mainta-
ined to sites at which it is abolished can cause local
re-excitation of the preparation. This mechanism,
termed phase 2 reentry, produces extrasystolic
beats capable of initiating circus movement reen-
try [142]. Phase 2 reentry has been shown to occur
when right ventricular epicardium is exposed to:
1) K+ channel openers such as pinacidil [143]; 2) so-
dium channel blockers such as flecainide [144];
3) increased [Ca2+] [115]; 4) calcium channel bloc-
kers such as verapamil; 5) metabolic inhibition
[145]; and 6) simulated ischemia [142].
Table 3 provides a list of the drugs thus far
identified as capable of inducing a Brugada ECG
phenotype. Antiarrhythmic agents exhibiting potent
use-dependent INa block have been shown to indu-
ce or unmask the Brugada ECG. These agents inc-
lude ajmaline, flecainide, procainamide, disopyrami-
de, propafenone and pilsicainide [146–148]. Antide-
pressants and antipsychotic agents have also been
reported to induce the Brugada pattern. A study of
98 patients experiencing an overdose of tricyclic
antidepressants reported that 15 of them displayed
an ECG consistent with BrS [149]. The overall
mortality was 3% among all patients but 6.7%
among patients that displayed a Brugada phenoty-
pe. Rouleau et al. [150] described 3 cases of psy-
chotropic drug-induced BrS ECG, occurring during
concomitant administration of amitryptiline and
a phenotiazine (case 1), overdose of fluoxetine (case 2),
and co-administration of trifluoperazine and loxapi-
ne (case 3). Babaliaros and Hurst [151] described
a Brugada pattern in patients receiving increasing
doses of imipramine. Akhtar and Goldschlager [152]
recently reported a case of BrS following overdose
of desipramine and clonazepam (Fig. 3). Chow et
al. [153] reported a similar case following desipra-
mine. Bolognesi et al. [154] described a Brugada
ECG pattern following overdose of amitryptyline
and with maprotiline. Two additional cases of BrS
were reported following overdose with nortryptili-
ne [155, 156] or lithium [157]. The available data
suggest most cases of antidepressant and antipsy-
chotic-induced BrS phenotype occurs as a conse-
quence of drug overdose or drug combination.
Exaggerated or otherwise abnormal J waves
have long been linked to idiopathic ventricular
fibrillation as well as to the BrS [116, 158–162]. The
Brugada syndrome is characterized by exaggerated
J wave that manifests as an ST segment elevation
in the right precordial leads [116]. A number of stu-
dies have highlighted the similarities between the
conditions that predispose to phase 2 reentry and
those that attend the appearance of the BrS. Loss
of the action potential dome in epicardium, but not
endocardium generates a transmural current that
Table 3. Drug-induced Brugada-like ECG patterns.
Modified from [213, 214], with permission.
I. Antiarrhythmic drugs
1. Na+ channel blockers
Class IC drugs (flecainide [146, 147, 196–198],
pilsicainide [199, 200], propafenone [201])
Class IA drugs (ajmaline [146, 202],
procainamide [146, 168], disopyramide [168, 203],
cibenzoline [204, 205])





1. Ca2+ channel blockers
Nifedipine, diltiazem
2. Nitrate
Isosorbide dinitrate, nitroglycerine [207]
3. K+ channel openers
Nicorandil
III. Psychotropic drugs
1. Tricyclic antidepressants [156]
Amitriptyline [150, 154], nortriptyline [155, 156],














1. Histaminic H1 receptor antagonists
Dimenhydrinate [209], diphenhydramine [210]
2. Cocaine intoxication [211, 212]
3. Alcohol intoxication
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manifests on the ECG as an ST segment elevation,
similar to that encountered in patients with the BrS
[99, 145, 163]. Evidence in support of a phase 2
reentrant mechanism in humans was recently pro-
vided by Thomsen et al. [164, 165].
Parasympathetic agonists like acetylcholine
facilitate loss of the action potential dome [166] by
suppressing ICa and/or augmenting potassium cur-
rent. Beta-adrenergic agonists restore the dome by
augmenting ICa. Agents that inhibit the sodium chan-
nel current facilitate loss of the canine right ventri-
cular action potential dome via a negative shift in
the voltage at which phase 1 begins [144, 167].
These findings are consistent with accentuation of
ST segment elevation in patients with the BrS fol-
lowing vagal maneuvers or Class I antiarrhythmic
agents as well as normalization of the ST segment
elevation following b adrenergic agents and pho-
sphodiesterase III inhibitors [99, 168, 169]. Loss of
the action potential dome is more readily induced
in right vs. left canine ventricular epicardium
[10, 145, 163] because of the more prominent
Ito-mediated phase 1 in action potentials in this region
of the heart. As previously noted, this distinction
is believed to be the basis for why the BrS is a right
ventricular disease.
In the past, much of the focus was on the abili-
ty of a reduction in sodium channel current to
unmask the BrS and create and arrhythmogenic
substrate. A recent report shows that a combina-
tion of INa and ICa block is more effective than INa
inhibition alone in precipitating the BrS in the ar-
terially-perfused wedge preparation [170].
The ST segment elevation associated with the
BrS has be attributed to: 1) conduction delay in the
right ventricular epicardial free wall in the region
of the outflow tract (RVOT) [171] and/or 2) accen-
tuation of the right ventricular epicardial action
potential that may lead to loss of the action poten-
tial dome [172]. The cellular mechanisms thought
to be responsible for the development of the Bru-
gada phenotype via hypothesis 2 is schematically
illustrated in Figure 4 [173, 174].
The ST segment is usually isoelectric becau-
se of the absence of transmural voltage gradients
at the level of the action potential plateau (Fig. 4A).
Accentuation of the right ventricular notch under
pathophysiologic conditions leads to exaggeration
of transmural voltage gradients and thus to accen-
tuation of the J wave or to J point elevation. When
epicardial repolarization precedes repolarization of
the cells in the M and endocardial regions the T
wave remains positive. This results in a saddleback
configuration of the repolarization waves (Fig. 4B).
Further accentuation of the notch may be accom-
panied by a prolongation of the epicardial action
potential such that the direction of repolarization
across the right ventricular wall and transmural
voltage gradients are reversed, leading to the de-
velopment of a coved-type ST segment elevation
and inversion of the T wave (Fig. 4C), typically ob-
served in the ECG of Brugada patients. A delay in
epicardial activation may also contribute to inver-
sion of the T wave. The downsloping ST segment
elevation observed in the experimental wedge mo-
dels often appears as an R’, suggesting that the ap-
pearance of a right bundle branch block (RBBB)
morphology in Brugada patients may be due at le-
ast in part to early repolarization of right ventricu-
lar (RV) epicardium, rather than major impulse con-
duction block in the right bundle.
Gussak et al. [175] pointed out that a majority
of RBBB-like morphologies encountered in cases
of BrS do not fit the criteria for RBBB. Moreover,
attempts by Miyazaki et al. [168] to record delayed
activation of the RV in Brugada patients met with
failure.
It is important to point out that although the
typical Brugada morphology is present in Figure 4B
and C, an arrhythmogenic substrate is absent. The
arrhythmogenic substrate is thought to develop
when a further shift in the balance of current leads
to loss of the action potential dome at some epicar-
dial sites but not others (Fig. 4D). Loss of the action
potential dome in epicardium but not endocardium
results in the development of a marked transmural
dispersion of repolarization and refractoriness, re-
sponsible for the development of a vulnerable win-
dow during which a premature impulse or extrasy-
stole can induce a reentrant arrhythmia. Conduc-
tion of the action potential dome from sites at which
it is maintained to sites at which it is lost causes
local re-excitation via a phase 2 reentry mechanism,
leading to the development of a very closely-coupled
extrasystole, which captures the vulnerable window
across the wall, thus triggering a circus movement
reentry in the form of VT/VF (Fig. 4E) [142, 176].
The phase 2 reentrant beat fuses with the T wave of
the basic response, thus accentuating the negative
T wave. This morphology is often observed in the
clinic preceding the onset of polymorphic VT.
Studies involving the arterially-perfused right
ventricular wedge preparation provide evidence in
support of these hypotheses [176]. Aiba et al. [177]
used a high resolution optical mapping system that
allows simultaneous recording of transmembrane action
potentials from 256 sites along the transmural surfa-
ce of the arterially-perfused canine right-ventricular
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wedge preparation to demonstrate that a steep repo-
larization gradient between the region at which the
dome is lost and the region at which it is maintained
is essential for the development of a closely coupled
phase 2 reentrant extrasystole. This study also sho-
wed that reentry initially rotates in the epicardium and
gradually shifts to a transmural orientation, responsi-
ble for nonsustained polymorphic VT or VF.
Kurita et al. placed monophasic action poten-
tial (MAP) electrodes on the epicardial and endo-
cardial surfaces of the RVOT in patients with the
BrS and demonstrated an accentuated notch in the
epicardial response, thus providing support for this
mechanism in humans [178, 179].
Thus, accentuation of the right ventricular epi-
cardial action potential notch underlies the ST seg-
ment elevation. Eventual loss of the dome of the
right ventricular epicardial action potential further
exaggerates ST segment elevation. A vulnerable
window is created both within epicardium, as well
as transmurally, which serves as the substrate for
the development of reentry (Fig. 5).
Phase 2 reentry provides the extrasystole that
serves as the trigger that precipitates episodes of
ventricular tachycardia and fibrillation in the BrS.
Evidence in support of this hypothesis was recen-
tly provided in an arterially-perfused canine right
ventricular experimental model of the BrS [176].
The VT and VF generated in these preparations is
usually polymorphic, resembling a rapid form of
torsade de pointes. This activity is likely related to
the migrating spiral wave shown to generate a pat-
tern resembling a polymorphic VT [180, 181].
Role of TDR in drug-induced
arrhythmogenesis
In the acquired long QT syndrome, QT inte-
rval increases as a function of drug concentration,
whereas in BrS it remains largely unchanged. What
these two drug-induced syndromes have in common
is an amplification of spatial dispersion of repolari-
zation, TDR in particular, which results in the de-
velopment of TdP when dispersion reaches the
threshold for reentry.
Genetic predisposition
The degree to which a genetic predisposition
contributes to the clinical manifestation of drug-
Figure 5. Proposed mechanism for the Brugada syndrome. A shift in the balance of currents serves to amplify
existing heterogeneities by causing loss of the action potential dome at some epicardial, but not endocardial sites.
A vulnerable window develops as a result of the dispersion of repolarization and refractoriness within epicardium as
well as across the wall. Epicardial dispersion leads to the development of phase 2 reentry, which provides the
extrasystole that captures the vulnerable window and initiates ventricular tachycardia/ventricular fibrillation (VT/VF)
via a circus movement reentry mechanism. Modified from [174], with permission.
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-induced arrhythmogenesis is not well defined. Ava-
ilable data suggest that up to 10–15% percent of in-
dividuals who develop TdP following exposure to
QT-prolonging drugs possess mutations associated
with the LQTS and may be considered to have a sub-
clinical form of the congenital syndrome [182–186].
Abbot et al. [187] were among the first to show
that a polymorphism (i.e., a genetic variation that
is present in greater than 1% of the population) in
an ion channel gene is associated with a predispo-
sition to drug-induced TdP. They identified a poly-
morphism (T8A) of the KCNE2 gene encoding for
MiRP, a beta subunit of the IKr channel, that is pre-
sent in 1.6% of the population and is associated with
TdP related to quinidine and to sulfamethoxazole/
/trimethoprim administration. This finding sugge-
sts that common genetic variations may increase
the risk for development of drug related arrhyth-
mias. Yang et al. [185] showed that DNA variants
in the coding regions of congenital long-QT dise-
ase genes predisposing to acquired LQTS can be
identified in approximately 10% to 15% of affected
subjects, predominantly in genes encoding ancilla-
ry subunits, providing further support for the hy-
pothesis that subclinical mutations and polymorphi-
sms may predispose to drug-induced TdP. Splaw-
ski et al. [188] further advanced this concept by
identifying a heterozygous polymorphism involving
substitution of serine with tyrosine in codon 1103
(S1103Y) in the sodium channel gene SCN5A
(S1102Y in the shorter splice variant of SCN5A)
among Africans and African Americans that incre-
ases the risk for acquired TdP. The polymorphism
was present in 57% of 23 patients with pro-arr-
hythmic episodes, but in only 13% of controls.
These findings suggest that carriers of such po-
lymorphisms can be identified and excluded from
treatment with drugs that are associated with
a risk of proarrhythmia. It is conceivable that such
testing could be applied widely since accurate
results could be made available rapidly at relati-
vely low cost.
Another common polymorphism that has been
associated with acquired forms of LQTS and TdP
is K897T in KCNH2 [189]. Most functional expres-
sion studies have reported that K897T reduces IKr,
[190–192] although one study has reported an in-
crease in HERG current [193].
The action of antidepressants to precipitate the
BrS may also have a genetic disposition. For exam-
ple, the SCN5A promoter haplotype (so-called Hap
B) has been shown to be associated with longer PR
and QRS intervals as well as a more exaggerated
response to sodium channel blockers [135].
Genetic defects can also contribute to drug-
induced channelopathies by influencing the meta-
bolism of drugs. In the case of relatively pure IKr
blockers, there is a clear relationship between pla-
sma levels of drug and the incidence of TdP. Gene-
tic variants of the genes encoding for enzymes re-
sponsible for drug metabolism could alter pharma-
cokinetics so as to cause wide fluctuations in plasma
levels, thus exerting a significant proarrhythmic
influence [194, 195]. For example, in the case of
cytochrome CYP2D6, which is involved in the me-
tabolism of some QT prolonging drugs (terodiline,
thioridazine), multiple polymorphisms have been
reported that reduce or eliminate its function;
5–10% of Caucasians and African-Americans lack
a functional CYP2D6. Numerous proteins, including
drug transport molecules and other drug metaboli-
zing enzymes, are involved in drug absorption,
distribution, and elimination and genetic variants of
each of these has the potential to modulate drug
concentrations and effects. Multiple substrates and
inhibitors of the cytochrome P450 enzymes have
been identified. A comprehensive database can be
found at http://medicine.iupui.edu/flockhart/.
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